Personalized neoantigen vaccination with synthetic long peptides

John P. Finnigan, Alex Rubinsteyn, , Nicholas Akers, Nina Bhardwaj, Jeff Hammerbacher, Bojan Losic & Eric Schadt
Mutations in cancer may give rise to novel antigenic peptides, known as tumor neoantigens, that are promising targets for immunotherapy. However, due to the complexity and heterogeneity of most cancers, a single antigenic target is often insufficient for achieving a durable response or remission. Vaccines using single, short synthetic peptides are vulnerable to immune evasion or may even promote immune tolerance and/or anergy, leading to increased tumor growth. Cancer vaccination has moved in two promising...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.